WO2023206985 - ROR1 ANTIBODY OR ROR1 /CD19 /CD3 TRI-SPECIFIC ANTIBODY FOR THE TREATMENT OF TUMORS
National phase entry:
Publication Number
WO/2023/206985
Publication Date
02.11.2023
International Application No.
PCT/CN2022/125623
International Filing Date
17.10.2022
Title **
[English]
ROR1 ANTIBODY OR ROR1 /CD19 /CD3 TRI-SPECIFIC ANTIBODY FOR THE TREATMENT OF TUMORS
[French]
ANTICORPS ROR1 OU ANTICORPS TRI-SPÉCIFIQUE ROR1/CD19/CD3 POUR LE TRAITEMENT DE TUMEURS
Applicants **
SHANDONG BOAN BIOTECHNOLOGY CO., LTD.
BOAN BOSTON LLC
NANJING BOAN BIOTECH CO. LTD
Inventors
WANG, Shuo
SONG, Deyong
DOU, Changlin
ZONG, Mengqi
JIAO, Jie
FENG, Jianxia
KAI, Xin
DANIELLA, Tatang
ZHANG, Yanan
DONG, Chuangchuang
Priority Data
202210425699.0
29.04.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1846 | |
| EPO | Filing, Examination, Granting | 11781 | |
| Japan | Filing, Examination, Granting | 2259 | |
| South Korea | Filing, Examination, Granting | 2307 | |
| USA | Filing, Examination, Granting | 7740 |
Total:
25,933
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present application provides an antibody or antigen binding fragment that binds to ROR1 or a variant thereof, and a multi-specific protein molecule (e.g. ROR1 /CD19 /CD3 tri-specific antibody) for the treatment of tumors with high expression of Receptor tyrosine kinase-like orphan receptor 1 (ROR1) or both Receptor tyrosine kinase-like orphan receptor 1 (ROR1) and CD19.[French]
La présente demande concerne un anticorps ou un fragment de liaison à l'antigène qui se lie à ROR1 ou un variant de celui-ci, et une molécule de protéine multi-spécifique (par exemple, un anticorps tri-spécifique ROR1/CD19/CD3) pour le traitement de tumeurs avec une expression élevée du récepteur orphelin 1 de type tyrosine kinase (ROR1) ou du récepteur 1 orphelin de type tyrosine kinase de récepteur (ROR1) et CD19.